4512 Stock Overview
Manufactures and sells ethical and non-prescription drugs in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Wakamoto Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥237.00 |
| 52 Week High | JP¥324.00 |
| 52 Week Low | JP¥189.00 |
| Beta | 0 |
| 11 Month Change | -0.84% |
| 3 Month Change | -5.20% |
| 1 Year Change | 19.10% |
| 33 Year Change | -14.13% |
| 5 Year Change | -12.87% |
| Change since IPO | -65.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4512 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.4% | 0.7% | -1.1% |
| 1Y | 19.1% | 10.1% | 10.7% |
Return vs Industry: 4512 exceeded the JP Pharmaceuticals industry which returned 10.1% over the past year.
Return vs Market: 4512 exceeded the JP Market which returned 10.7% over the past year.
Price Volatility
| 4512 volatility | |
|---|---|
| 4512 Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4512's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4512's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1929 | n/a | Arata Igarashi | www.wakamoto-pharm.co.jp |
Wakamoto Pharmaceutical Co.,Ltd. manufactures and sells ethical and non-prescription drugs in Japan. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation; and Wakamoto Intestinal Remedy drug.
Wakamoto Pharmaceutical Co.,Ltd. Fundamentals Summary
| 4512 fundamental statistics | |
|---|---|
| Market cap | JP¥8.35b |
| Earnings (TTM) | -JP¥222.00m |
| Revenue (TTM) | JP¥9.43b |
0.0x
P/S Ratio0.0x
P/E RatioIs 4512 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4512 income statement (TTM) | |
|---|---|
| Revenue | JP¥9.43b |
| Cost of Revenue | JP¥4.35b |
| Gross Profit | JP¥5.08b |
| Other Expenses | JP¥5.30b |
| Earnings | -JP¥222.00m |
Last Reported Earnings
Mar 31, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 4512 perform over the long term?
See historical performance and comparison